Premium
Schiff Base‐Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice
Author(s) -
Doğan Ayşegül,
Demirci Selami,
Türkmen Neşe Başak,
Çağlayan Ahmet Burak,
Aydın Safa,
Telci Dilek,
Kılıç Ertuğrul,
Şahin Kazım,
Orhan Cemal,
Tuzcu Mehmet,
Ekici Asiye Işın Doğan,
Şahin Fikrettin
Publication year - 2016
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.23229
Subject(s) - prostate cancer , medicine , cancer , in vivo , prostate , toxicity , metastasis , cancer research , pharmacology , pathology , biology , microbiology and biotechnology
BACKGROUND Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest. METHOD In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp‐C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity. RESULTS Results demonstrated that Heterodinuclear copper(II)Mn(II) complex‐P85 combination decreased tumor formation and tumor volume steadily over the course of experiments. CONCLUSIONS Overall, Heterodinuclear copper(II)Mn(II) complex‐P85 exerted remarkable anti‐cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016 . © 2016 Wiley Periodicals, Inc.